Use of Denosumab in an Aneurysmal Bone Cyst of the Spine. Case Report and Literature Review
Abstract
Vertebral tumors of the spine have a very low frequency. The incidence of aneurysmal bone cyst (ABC) ranges between 1% and 4% of all tumors. Its predominant location is the lumbar spine, to a greater extent, in the posterior arch. According to published studies, this condition behaves aggressively, due to the root compression generated by its expansion. While there is literature on the surgical treatment of the tumor and its en bloc resection and embolization, there is no experience on the treatment with monoclonal antibodies. There are very few published articles that corroborate a treatment for recurrences or for inoperable or intralesional aneurysmal bone cysts, which leave the possibility open to other techniques. We present the case of a 38-year-old woman with lumbar pain radiating to the thigh. In studies, a tumor was detected, and the needle biopsy and imaging confirmed that it was an aneurysmal bone cyst. We planned the treatment with preoperative embolization and intracompartmental excision by subsequent surgery with the release of the dural sac. At six months, tumor recurrence was observed. Treatment with denosumab was indicated for two years, periodic controls were carried out and the remission of symptoms and improvement in the images were verified.Downloads
References
Terzi S, Gasbarrini A, Fuiano M, Barbanti Brodano G, Ghermandi R, Bandiera S, et al. Efficacy and safety
of selective arterial embolization in the treatment of aneurysmal bone cyst of the mobile spine. Spine 2017;42(15):1130-8. https://doi.org/10.1097/BRS.0000000000002017
Ghermandi R, Terzi S, Gasbarrini A, Boriani S. Denosumab: non-surgical treatment option for selective arterial
embolization resistant aneurysmal bone cyst of the spine and sacrum. Case report. Eur Rev Med Pharmacol Sci
;20(17):3692-5. PMID: 27649673
Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 2013;22(6):1417-22.
https://doi.org/10.1007/s00586-013-2715-7
Namazi H. Letter regarding “Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts”. Eur Spine J 2013;22(10):2342. https://doi.org/10.1007/s00586-013-2951
Lange T, Schulte TL. Answer to the Letter to the Editor of H. Namazi concerning “Denosumab: a potential new
and innovative treatment option for aneurysmal bone cysts” by Lange T, Stehling C, Fröhlich B, Klingenhöfer
M, Kunkel P, Schneppenheim R, Escherich G, Gosheger G, Hardes J, Jürgens H, Schulte TL (2013), Eur Spine J; 22(6):1417-1422. Eur Spine J 2013;22(10):2343. https://doi.org/10.1007/s00586-013-2956-5
Patel RS, Dhamne AC, Kumar, GA, Kumar N. Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas. Eur Spine J 2018;27 (Suppl 3):S494-S500. https://doi.org/10.1007/s00586-018-5528-x
Kurucu N, Akyuz C, Ergen FB, Yalcin B, Aydin B, Varan A, et al. Denosumab treatment in aneurysmal bone cyst:
evaluation of nine cases. Pediatr Blood Cancer 2018;65(4):e26926. https://doi.org/10.1002/pbc.26926
Skubitz KM, Peltola JC, Santos RC, Cheng EY. Response of aneurysmal bone cyst to denosumab. Spine
;40(22):E1201-E1204. https://doi.org/10.1097/BRS.0000000000001027
Dubory A, Missenard G, Domont J, Court C. Interest of denosumab for the treatment of giant-cells tumors and
aneurysmal bone cysts of the spine. About nine cases. Spine 2016;41(11): E654-E660. https://doi.org/10.1097/BRS.0000000000001350
Charest-Morin R, Boriani S, Fisher CH, Patel S, Kawahara N, Mendel E, et al. Benign tumors of the spine. Has new chemotherapy and interventional radiology changed the treatment paradigm? Spine 2016;41(20):S178-S185.
https://doi.org/10.1097/BRS.0000000000001818
Bazán PL, Di Falco R, Borri AE, Medina M, Ciccioli NM, Danielle S. The use of denosumab in giant cell tumors in
sacrum. Coluna/Columna 2020;19(2):147-9. https://doi.org/10.1590/S1808-18512020190228839
Manuscript acceptance by the Journal implies the simultaneous non-submission to any other journal or publishing house. The RAAOT is under the Licencia Creative Commnos Atribución-NoComercial-Compartir Obras Derivadas Igual 4.0 Internacional (CC-BY-NC.SA 4.0) (http://creativecommons.org/licences/by-nc-sa/4.0/deed.es). Articles can be shared, copied, distributed, modified, altered, transformed into a derivative work, executed and publicly communicated, provided a) the authors and the original publication (Journal, Publisher and URL) are mentioned, b) they are not used for commercial purposes, c) the same terms of the license are maintained.
In the event that the manuscript is approved for its next publication, the authors retain the copyright and will assign to the journal the rights of publication, edition, reproduction, distribution, exhibition and communication at a national and international level in the different databases. data, repositories and portals.
It is hereby stated that the mentioned manuscript has not been published and that it is not being printed in any other national or foreign journal.
The authors hereby accept the necessary modifications, suggested by the reviewers, in order to adapt the manuscript to the style and publication rules of this Journal.
